"It Makes You Feel Like Someone Cares" acceptability of a financial incentive intervention for HIV viral suppression in the HPTN 065 (TLC-Plus) study

Elizabeth Greene, Allison Pack, Jill Stanton, Victoria Shelus, Elizabeth E Tolley, Jamilah Taylor, Wafaa M El Sadr, Bernard M Branson, Jason Leider, Natella Rakhmanina, Theresa Gamble, Elizabeth Greene, Allison Pack, Jill Stanton, Victoria Shelus, Elizabeth E Tolley, Jamilah Taylor, Wafaa M El Sadr, Bernard M Branson, Jason Leider, Natella Rakhmanina, Theresa Gamble

Abstract

Background: HPTN 065 (TLC-Plus) evaluated the feasibility and effectiveness of providing quarterly $70 gift card financial incentives to HIV-infected patients on antiretroviral therapy (ART) to encourage ART adherence and viral suppression, and represents the largest study to-date of a financial incentive intervention for HIV viral suppression. A post-trial qualitative substudy was undertaken to examine acceptability of the financial incentives among those receiving and implementing the intervention.

Methods: Between July and October 2013, semi-structured interviews were conducted with 72 patients and 12 investigators from 14 sites; three focus groups were conducted with 12 staff from 10 sites. Qualitative data collection elicited experiences with and attitudes about the intervention, including philosophical viewpoints and implementation experiences. Transcripts were analyzed in NVivo 10. Memos and matrices were developed to explore themes from different participant group perspectives.

Results: Patients, investigators, and staff found the intervention highly acceptable, primarily due to the emotional benefits gained through giving or receiving the incentive. Feeling rewarded or cared for was a main value perceived by patients; this was closely tied to the financial benefit for some. Other factors influencing acceptability for all included perceived effectiveness and health-related benefits, philosophical concerns about the use of incentives for health behavior change, and implementation issues. The termination of the incentive at the end of the study was disappointing to participants and unexpected by some, but generally accepted.

Conclusion: Positive experiences with the financial incentive intervention and strategies used to facilitate implementation led to high acceptability of the intervention, despite some reluctance in principle to the use of incentives. The findings of this analysis provide encouraging evidence in support of the acceptability of a large-scale financial incentive intervention for HIV viral suppression in a clinical setting, and offer valuable lessons for future applications of similar interventions.

Conflict of interest statement

The authors have read the journal′s policy and have the following conflicts: BMB was an employee of the Centers for Disease Control and Prevention during the design and data collection for this study. Since his retirement in October 2014, BMB has been selfemployed as Scientific Affairs LLC and provided ad hoc consulting services funded by the study for work related to review and revision of this manuscript. BMB also served as a consultant to Gilead Sciences, received speaking honoraria from Siemens Healthcare Diagnostics, and served as an expert witness on HIV testing. These did not in any way affect the design, conduct or presentation of results for this study, and do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. Other coauthors declare no competing interests exist.

References

    1. Lewden C, Chêne G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach aame mortality rates as the general population. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2007;46(1):72–7. 10.1097/QAI.0b013e318134257a
    1. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2009;50(5):529–36. 10.1097/QAI.0b013e31819675e9
    1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998;338(13):853–60. 10.1056/NEJM199803263381301
    1. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013;27(6):973–9. 10.1097/QAD.0b013e32835cae9c
    1. Sterne JAC, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. The Lancet.366(9483):378–84.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011;365(6):493–505. 10.1056/NEJMoa1105243
    1. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. Journal of Antimicrobial Chemotherapy. 2008;61(4):769–73. 10.1093/jac/dkn020
    1. Cooke CE, Lee HY, Xing S. Adherence to antiretroviral therapy in managed care members in the United States: a retrospective claims analysis. Journal of managed care pharmacy: JMCP. 2014;20(1):86–92. 10.18553/jmcp.2014.20.1.86
    1. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Jama. 2006;296(6):679–90. 10.1001/jama.296.6.679
    1. Nachega JB, Morroni C, Zuniga JM, Schechter M, Rockstroh J, Solomon S, et al. HIV treatment adherence, patient health literacy, and health care provider-patient communication: results from the 2010 AIDS treatment for life international survey. Journal of the International Association of Physicians in AIDS Care (JIAPAC). 2012;11:128–33.
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The Lancet. 2009;373(9657):48–57.
    1. Giles EL, Robalino S, McColl E, Sniehotta FF, Adams J. The effectiveness of financial incentives for health behaviour change: systematic review and meta-analysis. PloS One. 2014;9(3):e90347 10.1371/journal.pone.0090347
    1. Javanbakht M, Prosser P, Grimes T, Weinstein M, Farthing C. Efficacy of an individualized adherence support program with contingent reinforcement among nonadherent HIV-positive patients results from a randomized trial. Journal of the International Association of Physicians in AIDS Care (JIAPAC). 2006;5(4):143–50.
    1. Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, Balakrishnan P, et al. Voucher incentives improve linkage to and retention in care among HIV-infected drugs users in Chennai, India. Clinical Infectious Diseases. 2014:ciu324.
    1. Rosen MI, Dieckhaus K, McMahon TJ, Valdes B, Petry NM, Cramer J, et al. Improved adherence with contingency management. AIDS patient care and STDs. 2007;21(1):30–40. 10.1089/apc.2006.0028
    1. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug and alcohol dependence. 2007;88(1):54–63. 10.1016/j.drugalcdep.2006.09.019
    1. Giles EL, Robalino S, Sniehotta FF, Adams J, McColl E. Acceptability of financial incentives for encouraging uptake of healthy behaviours: a critical review using systematic methods. Preventive medicine. 2015;73:145–58. 10.1016/j.ypmed.2014.12.029
    1. Donnell DJ, Hall HI, Gamble T, Beauchamp G, Griffin AB, Torian LV, et al. Suppl 1: Use of HIV case surveillance system to design and evaluate site-randomized interventions in an HIV prevention study: HPTN 065. The open AIDS journal. 2012;6:122 10.2174/1874613601206010122
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Laboratory Testing: Department of Health and Human Services; 2015. p. C-6.
    1. Tolley EE, Ulin PR, Mack N, Robinson ET, Succop S. Qualitative methods in public health: a field guide for applied research. 2nd ed: John Wiley & Sons; 2016.
    1. Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, et al. A study of financial incentives to reduce plasma HIV RNA among patients in care. AIDS and Behavior. 2013;17(7):2293–300. 10.1007/s10461-013-0416-1
    1. Giles EL, Sniehotta FF, McColl E, Adams J. Acceptability of financial incentives and penalties for encouraging uptake of healthy behaviours: focus groups. BMC public health. 2015;15(1):58.
    1. Marteau TM, Ashcroft RE, Oliver A. Using financial incentives to achieve healthy behaviour. Bmj. 2009;338.
    1. Oliver A, Brown LD. A consideration of user financial incentives to address health inequalities. Journal of Health Politics, Policy and Law. 2012;37(2):201–26. 10.1215/03616878-1538602
    1. Petry NM. Contingency management treatments: controversies and challenges. Addiction. 2010;105(9):1507–9. 10.1111/j.1360-0443.2009.02879.x
    1. Promberger M, Brown RC, Ashcroft RE, Marteau TM. Acceptability of financial incentives to improve health outcomes in UK and US samples. Journal of medical ethics. 2011;37(11):682–7. 10.1136/jme.2010.039347
    1. Gneezy U, Meier S, Rey-Biel P. When and why incentives (don't) work to modify behavior. The Journal of Economic Perspectives. 2011:191–209.
    1. Promberger M, Dolan P, Marteau TM. “Pay them if it works”: Discrete choice experiments on the acceptability of financial incentives to change health related behaviour. Social science & medicine. 2012;75(12):2509–14.

Source: PubMed

3
구독하다